Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Inflammation
Erschienen in: Inflammation 4/2013

01.08.2013

Assessment of Oxidative, Inflammatory, and Fibrinolytic Biomarkers and DNA Strand Breakage in Hypercholesterolemia

verfasst von: Renata da Silva Pereira, Etiane Tatsch, Guilherme Vargas Bochi, Helena Kober, Thiago Duarte, Greice Franciele Feyh dos Santos Montagner, José Edson Paz da Silva, Marta Maria Medeiros Frescura Duarte, Ivana Beatrice Mânica da Cruz, Rafael Noal Moresco

Erschienen in: Inflammation | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to assess the levels of oxidative, inflammatory, and fibrinolytic biomarkers as well as DNA strand breakage in hypercholesterolemic subjects. Fasting glucose, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, uric acid, total protein, albumin, apolipoprotein (Apo) A, Apo B, advanced oxidation protein products (AOPP), increased ischemia-modified albumin (IMA), ―SH, NOx, IL-6, and D-dimer levels were assessed, and DNA strand breakage was evaluated using comet assay in 38 patients with hypercholesterolemia and 20 healthy controls. Total cholesterol, triglycerides, LDL cholesterol, Apo A, Apo B, AOPP, IMA, IL-6, and D-dimer concentrations were significantly higher in subjects with hypercholesterolemia. However, NOx and plasma ―SH group concentrations were lower in hypercholesterolemic subjects, while no significant differences were observed with respect to DNA strand breakage between the two groups. Hypercholesterolemia is related to oxidative stress and inflammation. Accordingly, AOPP concentration was higher in subjects with hypercholesterolemia, and we speculate that AOPP can reflect the enhancement of protein oxidation and inflammation.
Literatur
1.
Ghandehari, H., S. Kamal-Bahl, and N.D. Wong. 2008. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. American Heart Journal 156: 112–119.CrossRefPubMed
2.
Tailor, A., and D.N. Granger. 2003. Hypercholesterolemia promotes P-Selectin-dependent platelet-endothelial cell adhesion in postcapillary venules. Arteriosclerosis, Thrombosis, and Vascular Biology 23: 675–680.CrossRefPubMed
3.
Libby, P. 2000. Changing concepts of atherogenesis. Journal of Internal Medicine 247: 349–358.CrossRefPubMed
4.
Kotur-Stevuljevic, J., L. Memon, A. Stefanovic, S. Spasic, V. Spasojevic-Kalimanovska, N. Bogavac-Stanojevic, D. Kalimanovska-Ostric, Z. Jelic-Ivanovic, and G. Zunic. 2007. Correlation of oxidative stress parameters and inflammatory markers in coronary arterydisease patients. Clinical Biochemistry 40: 181–187.CrossRefPubMed
5.
Vassalle, C., L. Pratali, C. Boni, A. Mercuri, and R. Ndreu. 2008. An oxidative stress score as a combined measure of the pro-oxidant and anti-oxidant counterparts in patients with coronary artery disease. Clinical Biochemistry 41: 1162–1167.CrossRefPubMed
6.
7.
Olinsky, R., D. Garckowski, M. Foksinski, R. Rozalski, K. Roszkowski, and P. Jaruga. 2002. Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis, and acquired immunodeficiency syndrome. Free Radical Biology & Medicine 33(2): 192–200.CrossRef
8.
Andreassi, M.G. 2003. Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutation Research 543: 67–86.CrossRefPubMed
9.
Botto, N., A. Rizza, M.G. Colombo, A.M. Mazzone, S. Manfredi, S. Masetti, A. Clerico, A. Biagini, and M.G. Andreassi. 2001. Evidence for DNA damage in patients with coronary artery disease. Mutation Research 493: 23–30.CrossRefPubMed
10.
Bar-Or, D., E. Lau, and J.V. Winkler. 2000. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. The Journal of Emergency Medicine 19: 311–315.CrossRefPubMed
11.
Cichota, L.C., R.N. Moresco, M.M. Duarte, and J.E. Da Silva. 2008. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. Journal of Clinical Laboratory Analysis 22: 1–5.CrossRefPubMed
12.
Piva, S.J., M.M.F. Duarte, I.B.M. Da Cruz, A.C. Coelho, A.P. Moreira, R. Tonello, S.C. Garcia, and R.N. Moresco. 2011. Ischemia-modified albumin as na oxidative stress biomarker in obesity. Clinical Biochemistry 44: 345–347.CrossRefPubMed
13.
Kaefer, M., S.J. Piva, J.A. De Carvalho, D.B. Da Silva, A.M. Becker, A.C. Coelho, M.M. Duarte, and R.N. Moresco. 2010. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clinical Biochemistry 43: 450–454.CrossRefPubMed
14.
Gottlieb, M.G.V., I.B.M. Da Cruz, M.M.F. Duarte, R.N. Moresco, M. Wiehe, C.H. Schwanke, and L.C. Bonadese. 2010. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. Journal of Clinical Endocrinology and Metabolism 95: 586–591.CrossRef
15.
Duarte, M.M., J.B. Rocha, R.N. Moresco, T. Duarte, I.B.M. Da Cruz, V.L. Loro, and M.R. Schetinger. 2009. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clinical Biochemistry 42: 666–671.CrossRefPubMed
16.
Witko-Sarsat, V., M. Friedlander, C. Capeillère-Blandin, T. Nguyen-Khoa, A.T. Nguyen, J. Zingraff, P. Jungers, and B. Descamps-Latscha. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 49: 1304–1313.CrossRefPubMed
17.
Drüeke, T., V. Witko-Sarsat, Z. Massy, B. Descamps-Latscha, A.P. Guerin, S.J. Marchais, V. Gausson, and G.M. London. 2002. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212–2217.CrossRefPubMed
18.
Descamps-Latscha, B., V. Witko-Sarsat, T. Nguyen-Khoa, A.T. Nguyen, V. Gausson, N. Mothu, G.M. London, and P. Jungers. 2005. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. American Journal of Kidney Diseases 45: 39–47.CrossRefPubMed
19.
Nedeljkovic, Z.S., N. Gokce, and J. Loscalzo. 2003. Mechanisms of oxidative stress and vascular dysfunction. Postgraduate Medical Journal 79: 195–200.CrossRefPubMed
20.
Armstrong, E.J., D.A. Morrow, and M.S. Sabatine. 2006. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation 113: 72–75.CrossRef
21.
Vita, J.A., C.B. Treasure, E.G. Nabel, J.M. McLenachan, R.D. Fish, A.C. Yeung, V.I. Veksthein, A.P. Selwyn, and P. Ganz. 1990. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81: 491–497.CrossRefPubMed
22.
Francisco, G., C. Hernández, and R. Simó. 2006. Serum markers of vascular inflammation in dyslipemia. Clinica Chimica Acta 369: 1–16.CrossRef
23.
Lowe, G.D.O., J.W.G. Yarnell, A. Rumley, D. Bainton, and D.M. Sweetnam. 2001. C-reactive protein, fibrin D-dimer and incident ischemic heart disease in the Speedwell Study. Are inflammation and fibrin turnover linked in pathogenesis? Arteriosclerosis, Thrombosis, and Vascular Biology 21: 603–610.CrossRefPubMed
24.
Lowe, G.D.O., A. Rumley, A.D. Mchahon, I. Ford, D.S.J. O’Reilly, and C.J. Packard. 2004. Interleukin-6, fibrin D-dimer, an coagulation factors VII and XIIa in prediction of coronary heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 1529–1524.CrossRefPubMed
25.
Sakamotok, K., Y. Yamamoto, H. Okamatsu, and M. Okabe. 2011. D-dimer is helpful for differentiating acute aortic dissection and acute pulmonary embolism from acute myocardial infarction. Hellenic Journal of Cardiology 52(2): 123–127.
26.
Skilton, M.R., P. Moulin, A. Sérusclat, P. Nony, and F. Bonnet. 2007. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis 190: 416–422.CrossRefPubMed
27.
Friedewald, W.T., R.I. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18: 499–502.PubMed
28.
Ellman, G.L. 1959. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 82: 70–77.CrossRefPubMed
29.
Tatsch, E., G.V. Bochi, R.S. Pereira, H. Kober, V.A. Agertt, M.M.A. De Campos, P. Gomes, M.M. Duarte, and R.N. Moresco. 2011. A simple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clinical Biochemistry 44: 348–350.CrossRefPubMed
30.
Selmeci, L., L. Seres, M. Antal, J. Lukács, A. Regöly-Méreia, and G. Acsády. 2005. Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: a simple, fast and inexpensive automated technique. Clinical Chemistry and Laboratory Medicine 43: 294–297.CrossRefPubMed
31.
McKelvey-Martin, V.J., M.H. Green, P. Schmezer, B.L. Pool-Zobel, M.P. De Méo, and A. Collins. 1993. The single cell gel electrophoresis assay (comet assay): a European review. Mutation Research 288: 47–63.CrossRefPubMed
32.
Singh, N., M. McCoy, R. Tice, and E. Schneider. 1995. A simple technique for quantification of low levels of DNA damage in individuals cells. Experimental Cell Research 175: 184–191.CrossRef
33.
Tice, R.R., D. Agurell, D. Anderson, B. Burlinson, A. Hartmann, H. Kobayashi, Y. Miyamae, E. Rojas, J.C. Ryu, and Y.F. Sasaki. 2000. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environmental and Molecular Mutagenesis 35: 206–221.CrossRefPubMed
34.
Hartmann, A., E. Agurell, C. Beevers, S. Brendler-Schwaab, B. Burlinson, P. Clay, A. Collins, G. Smith, G. Speit, V. Thybaud, and R.R. Tice. 2003. Recommendations for conducting the in vivo alkaline comet assay. Mutagenesis 18: 45–51.CrossRefPubMed
35.
Nadin, S., L. Vargas-Roig, and D. Ciocca. 2001. A silver staining method for single-cell gel assay. Journal of Histochemistry and Cytochemistry 49: 1183–1186.CrossRefPubMed
36.
Marsche, G., S. Frank, A. Hrzenjak, M. Holzer, S. Dirnberger, C. Wadsack, H. Scharnagl, T. Stojakovic, A. Heinemann, and K. Oettl. 2009. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circulation Research 104: 750–757.CrossRefPubMed
37.
Redón, J., M.R. Oliva, C. Tormos, V. Giner, J. Chaves, A. Iradi, and G.T. Sáez. 2003. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 41: 1096–1101.CrossRefPubMed
38.
Roy, D., J. Quiles, D.C. Gaze, P. Collinson, J.C. Kaski, and G.F. Baxter. 2006. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 92: 113–114.CrossRefPubMed
39.
Roy, D., and J.C. Kaski. 2007. Ischemia-modified albumin: the importance of oxidative stress. Journal of the American College of Cardiology 49: 2375–2376.CrossRefPubMed
40.
Abramson, J.L., W.C. Hooper, D.P. Jones, S. Ashfaq, S.D. Rhodes, W.S. Weintraub, D.G. Harrisson, A.A. Quyyumi, and V. Vacarinno. 2005. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis 178: 115–121.CrossRefPubMed
41.
Aydin, S., H. Uzun, V. Sozer, and T. Altug. 2009. Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits. Pharmacological Research 59: 242–247.CrossRefPubMed
42.
Pandey, K.B., N. Mishra, and S.I. Rizvi. 2010. Protein oxidation biomarkers in plasma of type 2 diabetic patients. Clinical Biochemistry 43: 508–511.CrossRefPubMed
43.
Kelly, C.J., A. Speirs, G.W. Gould, J.R. Petrie, H. Lyall, and J.M. Connell. 2002. Altered vascular function in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 87: 742–746.CrossRefPubMed
44.
Piwowar, A., M.K. Kordecka, and M. Warwas. 2007. AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 77: 188–192.CrossRefPubMed
45.
Kaya, C., A.F. Erkan, S.D. Cengiz, I. Dünder, O.E. Demirel, and A. Bilgihan. 2009. Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycist ovary syndrome. Fertility and Sterility 92: 1372–1377.CrossRefPubMed
46.
Liu, S.X., F.F. Hou, Z.J. Guo, R. Nagai, W.R. Zhang, Z.Q. Liu, Z.M. Zhou, M. Zhou, D. Xie, G.B. Wang, and X. Zhang. 2006. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 1156–1162.CrossRefPubMed
47.
Mercer, J.R., K.K. Cheng, N. Figg, I. Gorenne, M. Mahmoudi, J. Griffin, and A. Vidal-Puig. 2010. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circulation Research 107: 1021–1031.CrossRefPubMed
48.
Harangi, M., E. Remenyik, I. Seres, Z. Varga, E. Katona, and G. Paragh. 2002. Determination of DNA damage induced by oxidative stress in hyperlipidemic patients. Mutation Research 513: 17–25.CrossRefPubMed
49.
Dalboni, S., B.P. Campagnaro, C.L. Tonin, E.C. Vasquez, and S.S. Meyrelles. 2012. The concurrence of hypercholesterolemia and aging promotes DNA damage in apolipoprotein E-deficient mice. Open Journal of Blood Diseases 2: 51–55.CrossRef
50.
Madamanchi, N.R., R. Zhou, A.E. Vendrov, X. Niu, and M.S. Runge. 2010. Does oxidative DNA damage cause atherosclerosis and metabolic syndrome? Circulation Research 107: 940–942.CrossRefPubMed
51.
Bermudez, E.A., N. Rifai, J. Buring, J.E. Manson, and P.M. Ridker. 2002. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arteriosclerosis, Thrombosis, and Vascular Biology 22: 1668–1673.CrossRefPubMed
52.
Porreca, E., C. Di Febbo, A. Di Castelnuovo, G. Baccante, C. Amore, A. Angelini, M. Di Nisio, M. Donati, F. Cuccurullo, and L. Iacoviello. 2002. Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients. Atherosclerosis 165: 159–166.CrossRefPubMed
53.
Kearon, C., J.S. Ginsberg, J. Douketis, M. Crowther, P. Brill-Edwards, J.I. Weitz, and J. Hirsh. 2001. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Annals of Internal Medicine 135: 108–111.CrossRefPubMed
54.
Moresco, R.N., L.C.R. Vargas, R. Halla-Junior, and L.M.R. Silla. 2005. Lack of association between cardiac troponin T and D-Dimer in the evaluation of myocardial damage. Journal of Clinical Laboratory Analysis 19: 282–284.CrossRefPubMed
55.
Lee, A.J., F.G. Fowkes, G.D. Lowe, and A. Rumley. 1995. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thrombosis and Haemostasis 74: 828–832.PubMed
56.
McDermott, M.M., P. Greenland, D. Green, J.M. Guralnik, M.H. Criqui, K. Liu, C. Chan, W.H. Pearse, L. Taylor, P.M. Ridker, J.R. Schneider, G. Martin, N. Rifai, and M. Quann. 2003. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 107: 3191–3198.CrossRefPubMed
57.
Rajavashisth, T.B., X.P. Xu, S. Jovinge, S. Meisel, X.O. Xu, N.N. Chai, M.C. Fishbein, S. Kaul, B. Cercek, B. Sharifi, and P.K. Shah. 1999. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 99: 3103–3109.CrossRefPubMed
58.
Rao, K.M., C.S. Pieper, M.S. Currie, and H.J. Cohen. 1994. Variability of plasma IL-6 and crosslinked fibrin dimers over time in community dwelling elderly subjects. American Journal of Clinical Pathology 102: 802–805.PubMed
59.
Harrison, D.G. 1996. Endothelial control of vasomotion and nitric oxide production: a potential target for risk factor management. Cardiology Clinics 14: 1–15.CrossRefPubMed
60.
Siekmeier, R., T. Grammer, and W. März. 2008. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. Journal of Cardiovascular Pharmacology and Therapeutics 13: 279–297.CrossRefPubMed
61.
Harrison, D.G. 1997. Cellular and molecular mechanisms of endothelial cell dysfunction. Journal of Clinical Investigation 100: 2153–2157.CrossRefPubMed
62.
Sposito, A.C. 2004. Emerging insights into hypertension and dyslipidaemia synergies. European Heart Journal 6(Suppl): G8–G12.
63.
Tousoulis, D., A.M. Kampoliam, C. Tentolouris, N. Papageorgiou, and C. Stefanadis. 2012. The role of nitric oxide on endothelial function. Current Vascular Pharmacology 10: 4–18.CrossRefPubMed
64.
Feron, O., C. Dessy, S. Moniotte, J.P. Desager, and J.L. Balligand. 1999. Hipercholesterolemia decrease nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. Journal of Clinical Investigation 03: 897–905.CrossRef
65.
Stefan, J., M. Schlaich, M. Langenfeld, H. Weihprecht, G. Schmitz, G. Weidinger, and R.E. Schemieder. 1998. Incresed bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. Circulation 98: 211–216.CrossRef
66.
Rahman, M.M., Z. Varghese, and J.F. Moorhead. 2001. Paradoxical increase in nitric oxide synthase activity in hypercholesterolaemic rats with impaired renal function and decreased activity of nitric oxide. Nephrology, Dialysis, Transplantation 16: 262–268.CrossRefPubMed
Metadaten
Titel
Assessment of Oxidative, Inflammatory, and Fibrinolytic Biomarkers and DNA Strand Breakage in Hypercholesterolemia
verfasst von
Renata da Silva Pereira
Etiane Tatsch
Guilherme Vargas Bochi
Helena Kober
Thiago Duarte
Greice Franciele Feyh dos Santos Montagner
José Edson Paz da Silva
Marta Maria Medeiros Frescura Duarte
Ivana Beatrice Mânica da Cruz
Rafael Noal Moresco
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2013
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9614-2

Weitere Artikel der Ausgabe 4/2013

Inflammation 4/2013 Zur Ausgabe

OriginalPaper

T-Cell Immunoglobulin- and Mucin-Domain-Containing Molecule 3 Genetic Variants and HIV+ Non-Hodgkin Lymphomas

OriginalPaper

Therapeutic Effects of NK-HDAC-1, a Novel Histone Deacetylase Inhibitor, on Collagen-Induced Arthritis Through the Induction of Apoptosis of Fibroblast-Like Synoviocytes

OriginalPaper

The Detection of Vascular Endothelial Growth Factor in Serum of Patients with Hemorrhagic Fever with Renal Syndrome

OriginalPaper

Magnolol Pretreatment Prevents Sepsis-Induced Intestinal Dysmotility by Maintaining Functional Interstitial Cells of Cajal

OriginalPaper

Comprehensive Profiling of Peripheral Immune Cells and Subsets in Patients with Intermittent Allergic Rhinitis Compared to Healthy Controls and After Treatment with Glucocorticoids

OriginalPaper

C-Reactive Protein Measurements as a Marker of the Severity of Chronic Obstructive Pulmonary Disease Exacerbations

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise